Gregg Williams Acquires 10,623 Shares of Second Sight Medical Products Inc (EYES) Stock

Second Sight Medical Products Inc (NASDAQ:EYES) Director Gregg Williams bought 10,623 shares of Second Sight Medical Products stock in a transaction dated Monday, August 27th. The stock was acquired at an average cost of $1.57 per share, for a total transaction of $16,678.11. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Gregg Williams also recently made the following trade(s):

  • On Thursday, August 23rd, Gregg Williams bought 17,052 shares of Second Sight Medical Products stock. The stock was acquired at an average cost of $1.63 per share, for a total transaction of $27,794.76.
  • On Monday, August 20th, Gregg Williams bought 4,110 shares of Second Sight Medical Products stock. The stock was acquired at an average cost of $1.57 per share, for a total transaction of $6,452.70.
  • On Friday, August 17th, Gregg Williams bought 7,800 shares of Second Sight Medical Products stock. The stock was acquired at an average cost of $1.56 per share, for a total transaction of $12,168.00.
  • On Wednesday, August 15th, Gregg Williams bought 3,247,362 shares of Second Sight Medical Products stock. The stock was acquired at an average cost of $1.55 per share, for a total transaction of $5,033,411.10.
  • On Monday, August 13th, Gregg Williams bought 7,000 shares of Second Sight Medical Products stock. The stock was acquired at an average cost of $1.60 per share, for a total transaction of $11,200.00.
  • On Thursday, August 9th, Gregg Williams bought 22,509 shares of Second Sight Medical Products stock. The stock was acquired at an average cost of $1.57 per share, for a total transaction of $35,339.13.
  • On Monday, August 6th, Gregg Williams bought 8,188 shares of Second Sight Medical Products stock. The stock was acquired at an average cost of $1.66 per share, for a total transaction of $13,592.08.
  • On Friday, July 27th, Gregg Williams acquired 23,749 shares of Second Sight Medical Products stock. The shares were purchased at an average cost of $1.62 per share, for a total transaction of $38,473.38.
  • On Wednesday, July 25th, Gregg Williams acquired 10,402 shares of Second Sight Medical Products stock. The shares were purchased at an average cost of $1.60 per share, for a total transaction of $16,643.20.
  • On Monday, July 23rd, Gregg Williams acquired 24,476 shares of Second Sight Medical Products stock. The shares were purchased at an average cost of $1.67 per share, for a total transaction of $40,874.92.

NASDAQ:EYES traded up $0.01 during trading hours on Monday, hitting $1.57. 183,100 shares of the stock were exchanged, compared to its average volume of 409,970. Second Sight Medical Products Inc has a twelve month low of $1.05 and a twelve month high of $2.58. The company has a market cap of $104.64 million, a price-to-earnings ratio of -2.66 and a beta of 3.08.

Second Sight Medical Products (NASDAQ:EYES) last posted its quarterly earnings data on Tuesday, August 7th. The medical device company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.02. Second Sight Medical Products had a negative return on equity of 432.45% and a negative net margin of 418.82%. The firm had revenue of $1.91 million for the quarter, compared to the consensus estimate of $2.21 million. analysts forecast that Second Sight Medical Products Inc will post -0.58 EPS for the current fiscal year.

An institutional investor recently bought a new position in Second Sight Medical Products stock. Glassman Wealth Services acquired a new position in shares of Second Sight Medical Products Inc (NASDAQ:EYES) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 72,366 shares of the medical device company’s stock, valued at approximately $139,000. Glassman Wealth Services owned approximately 0.12% of Second Sight Medical Products as of its most recent filing with the Securities and Exchange Commission. 10.79% of the stock is owned by institutional investors and hedge funds.

Several research analysts have issued reports on the company. Zacks Investment Research downgraded Second Sight Medical Products from a “hold” rating to a “sell” rating in a report on Monday, August 13th. HC Wainwright set a $5.00 price objective on Second Sight Medical Products and gave the stock a “buy” rating in a report on Wednesday, August 8th. Finally, ValuEngine raised Second Sight Medical Products from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc, together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. It offers Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa.

Read More: Marijuana Stocks

Insider Buying and Selling by Quarter for Second Sight Medical Products (NASDAQ:EYES)

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply